Upsher-Smith to Showcase Innovations at the American Epilepsy Society Meeting
Upsher-Smith Laboratories, LLC is set to play a significant role at the upcoming Annual Meeting of the American Epilepsy Society. The event will take place shortly, where Upsher-Smith will take the opportunity to highlight several presentations and showcase their innovative treatment options.
Participation Highlights at AES 2024
Discussing the forthcoming event, Upsher-Smith announced its participation at AES 2024, which is poised to occur in Los Angeles. This annual event gathers professionals to share insights and advancements in the field of epilepsy. The company will present details on its medications designed for catering to infantile spasms, among other areas.
Focus on Infantile Spasms Treatment
One of the key focuses for Upsher-Smith during the meeting will be its newly acquired product VIGAFYDE™ (vigabatrin) Oral Solution. VIGAFYDE™ stands out as the first ready-to-use vigabatrin oral solution and is specifically crafted for infants aged one month to two years suffering from infantile spasms. Importantly, this new offering represents the first new drug application approved for this condition in the past fifteen years, making waves in the treatment options available to patients and their families.
Innovation Pavilion Presentations
During the AES conference, attendees are encouraged to visit the Innovation Pavilion for presentations focusing on vigabatrin. These sessions will occur at designated times on specific dates during the meeting. The Innovation Pavilion will serve as a significant hub for information on advances in treatments.
Insightful Scientific Posters
Beyond presentations, the company will also showcase scientific posters detailing vital research findings. These posters will cover newly gathered data which underpins the efficacy and research surrounding their vigabatrin products, further enriching the discussion among attending professionals.
Engagement Opportunities
Upsher-Smith representatives will be present in their commercial booths during the conference, eager to engage with healthcare professionals. They will discuss the significant components of their product line, including their latest vigabatrin solution and the consistent support framework provided through their Promise of Support™ Program.
About Upsher-Smith and Its Commitment
The company emphasizes its commitment to enhancing the lives of patients through continual support. The Promise of Support™ Program stands out as a cornerstone of Upsher-Smith's dedication, providing various resources aimed at assisting patients along their treatment journey while focusing on education and support for families.
Vigabatrin REMS and Safety Information
All vigabatrin offerings are subject to stringent guidelines enforced by the FDA through a Risk Evaluation and Mitigation Strategy (REMS). This compliance is crucial in ensuring that healthcare providers remain informed about the risks and benefits associated with vigabatrin use, particularly regarding potential vision loss.
Frequently Asked Questions
What is the main goal of Upsher-Smith at AES 2024?
Upsher-Smith aims to showcase its innovative products and engage with healthcare professionals regarding advancements in epilepsy treatments, specifically for infantile spasms.
What is VIGAFYDE™?
VIGAFYDE™ is a newly approved vigabatrin oral solution designed for infants aged 1 month to 2 years, aimed at treating infantile spasms.
How does the Promise of Support™ Program assist patients?
This program offers comprehensive support including education, medication supply, and prior authorization aid to enhance patients' and families' experiences.
What kind of information will be presented at the Innovation Pavilion?
The Innovation Pavilion will feature several presentations dedicated to new findings related to vigabatrin and its use in treating infantile spasms.
What safety measures are in place for vigabatrin products?
All vigabatrin products are administered under Rigorous REMS to ensure safety and effectiveness, emphasizing the need for ongoing vision assessments.
